1. Scrip
  2. >>New Products

Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL

Agency Denied Donanemab Accelerated Approval In January

 
• By Mandy Jackson

With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.

Skid marks in front of speed bump on a asphalt country road
The mirikizumab CRL is Lilly's second bump in the road with the FDA in 2023 • Source: Shutterstock

Eli Lilly and Company started 2023 on a high, preparing for five big US Food and Drug Administration approvals of new products or new indications. The year is not going as smoothly as the company had hoped, however, with the FDA issuing a complete response letter (CRL) rejecting mirikizumab as a treatment for ulcerative colitis due to concerns about manufacturing for the IL-23 inhibitor.

The CRL, which Lilly announced on 13 April, gives the Indianapolis-based drug maker a 1-for-3 record so far this year,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By Manas Mishra

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.